TISIDB

Summary
Symbol	HSD17B4
Name	hydroxysteroid (17-beta) dehydrogenase 4
Aliases	MFE-2; SDR8C1; 17beta-estradiol dehydrogenase type IV; peroxisomal multifunctional protein 2; 17-beta-HSD IV ......
Chromosomal Location	5q2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Peroxisome.
Domain	PF00106 short chain dehydrogenase PF01575 MaoC like domain PF02036 SCP-2 sterol transfer family
Function	Bifunctional enzyme acting on the peroxisomal beta-oxidation pathway for fatty acids. Catalyzes the formation of 3-ketoacyl-CoA intermediates from both straight-chain and 2-methyl-branched-chain fatty acids.

> Gene Ontology [ TOP ]
Biological Process	GO:0000038 very long-chain fatty acid metabolic process GO:0001503 ossification GO:0001649 osteoblast differentiation GO:0001676 long-chain fatty acid metabolic process GO:0002064 epithelial cell development GO:0006631 fatty acid metabolic process GO:0006635 fatty acid beta-oxidation GO:0006637 acyl-CoA metabolic process GO:0006694 steroid biosynthetic process GO:0006699 bile acid biosynthetic process GO:0006732 coenzyme metabolic process GO:0006790 sulfur compound metabolic process GO:0007548 sex differentiation GO:0008202 steroid metabolic process GO:0008206 bile acid metabolic process GO:0008209 androgen metabolic process GO:0008210 estrogen metabolic process GO:0008406 gonad development GO:0008584 male gonad development GO:0009062 fatty acid catabolic process GO:0010817 regulation of hormone levels GO:0016042 lipid catabolic process GO:0016053 organic acid biosynthetic process GO:0016054 organic acid catabolic process GO:0019395 fatty acid oxidation GO:0030258 lipid modification GO:0033540 fatty acid beta-oxidation using acyl-CoA oxidase GO:0034440 lipid oxidation GO:0034754 cellular hormone metabolic process GO:0035337 fatty-acyl-CoA metabolic process GO:0035383 thioester metabolic process GO:0036109 alpha-linolenic acid metabolic process GO:0036111 very long-chain fatty-acyl-CoA metabolic process GO:0036112 medium-chain fatty-acyl-CoA metabolic process GO:0042445 hormone metabolic process GO:0044242 cellular lipid catabolic process GO:0044282 small molecule catabolic process GO:0044283 small molecule biosynthetic process GO:0045137 development of primary sexual characteristics GO:0046394 carboxylic acid biosynthetic process GO:0046395 carboxylic acid catabolic process GO:0046546 development of primary male sexual characteristics GO:0046661 male sex differentiation GO:0048608 reproductive structure development GO:0051186 cofactor metabolic process GO:0060008 Sertoli cell differentiation GO:0060009 Sertoli cell development GO:0061458 reproductive system development GO:0072329 monocarboxylic acid catabolic process GO:0072330 monocarboxylic acid biosynthetic process
Molecular Function	GO:0003857 3-hydroxyacyl-CoA dehydrogenase activity GO:0016229 steroid dehydrogenase activity GO:0016508 long-chain-enoyl-CoA hydratase activity GO:0016614 oxidoreductase activity, acting on CH-OH group of donors GO:0016616 oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor GO:0016829 lyase activity GO:0016835 carbon-oxygen lyase activity GO:0016836 hydro-lyase activity GO:0016853 isomerase activity GO:0033764 steroid dehydrogenase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor GO:0033989 3alpha,7alpha,12alpha-trihydroxy-5beta-cholest-24-enoyl-CoA hydratase activity GO:0044594 17-beta-hydroxysteroid dehydrogenase (NAD+) activity
Cellular Component	GO:0005777 peroxisome GO:0005778 peroxisomal membrane GO:0005782 peroxisomal matrix GO:0031903 microbody membrane GO:0031907 microbody lumen GO:0042579 microbody GO:0044438 microbody part GO:0044439 peroxisomal part

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04146 Peroxisome hsa00120 Primary bile acid biosynthesis hsa01100 Metabolic pathways
Reactome	R-HSA-389887: Beta-oxidation of pristanoyl-CoA R-HSA-390247: Beta-oxidation of very long chain fatty acids R-HSA-194068: Bile acid and bile salt metabolism R-HSA-1430728: Metabolism R-HSA-556833: Metabolism of lipids and lipoproteins R-HSA-390918: Peroxisomal lipid metabolism R-HSA-192105: Synthesis of bile acids and bile salts R-HSA-193368: Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol R-HSA-2046104: alpha-linolenic (omega3) and linoleic (omega6) acid metabolism R-HSA-2046106: alpha-linolenic acid (ALA) metabolism

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04146 Peroxisome
hsa00120 Primary bile acid biosynthesis
hsa01100 Metabolic pathways

Reactome

R-HSA-389887: Beta-oxidation of pristanoyl-CoA
R-HSA-390247: Beta-oxidation of very long chain fatty acids
R-HSA-194068: Bile acid and bile salt metabolism
R-HSA-1430728: Metabolism
R-HSA-556833: Metabolism of lipids and lipoproteins
R-HSA-390918: Peroxisomal lipid metabolism
R-HSA-192105: Synthesis of bile acids and bile salts
R-HSA-193368: Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol
R-HSA-2046104: alpha-linolenic (omega3) and linoleic (omega6) acid metabolism
R-HSA-2046106: alpha-linolenic acid (ALA) metabolism

Summary
Symbol	HSD17B4
Name	hydroxysteroid (17-beta) dehydrogenase 4
Aliases	MFE-2; SDR8C1; 17beta-estradiol dehydrogenase type IV; peroxisomal multifunctional protein 2; 17-beta-HSD IV ......
Chromosomal Location	5q2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between HSD17B4 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	HSD17B4
Name	hydroxysteroid (17-beta) dehydrogenase 4
Aliases	MFE-2; SDR8C1; 17beta-estradiol dehydrogenase type IV; peroxisomal multifunctional protein 2; 17-beta-HSD IV ......
Chromosomal Location	5q2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of HSD17B4 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	logFC: -2.36; FDR: 0.02860	Resistant to T cell-mediated killing
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	HSD17B4
Name	hydroxysteroid (17-beta) dehydrogenase 4
Aliases	MFE-2; SDR8C1; 17beta-estradiol dehydrogenase type IV; peroxisomal multifunctional protein 2; 17-beta-HSD IV ......
Chromosomal Location	5q2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of HSD17B4 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.196	0.435
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.04	0.987
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.313	0.853
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.302	0.293
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.187	0.929
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.443	0.859
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.074	0.859
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.013	0.994
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.144	0.946
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.035	0.987
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.193	0.954
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.016	0.834

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of HSD17B4 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	1.4	2.3	0.469
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	1.7	2	0.532
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	5.9	-5.9	0.447
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	9.1	-9.1	0.458
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	HSD17B4
Name	hydroxysteroid (17-beta) dehydrogenase 4
Aliases	MFE-2; SDR8C1; 17beta-estradiol dehydrogenase type IV; peroxisomal multifunctional protein 2; 17-beta-HSD IV ......
Chromosomal Location	5q2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of HSD17B4. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	HSD17B4
Name	hydroxysteroid (17-beta) dehydrogenase 4
Aliases	MFE-2; SDR8C1; 17beta-estradiol dehydrogenase type IV; peroxisomal multifunctional protein 2; 17-beta-HSD IV ......
Chromosomal Location	5q2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of HSD17B4. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by HSD17B4. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	HSD17B4
Name	hydroxysteroid (17-beta) dehydrogenase 4
Aliases	MFE-2; SDR8C1; 17beta-estradiol dehydrogenase type IV; peroxisomal multifunctional protein 2; 17-beta-HSD IV ......
Chromosomal Location	5q2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of HSD17B4. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	HSD17B4
Name	hydroxysteroid (17-beta) dehydrogenase 4
Aliases	MFE-2; SDR8C1; 17beta-estradiol dehydrogenase type IV; peroxisomal multifunctional protein 2; 17-beta-HSD IV ......
Chromosomal Location	5q2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of HSD17B4 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	HSD17B4
Name	hydroxysteroid (17-beta) dehydrogenase 4
Aliases	MFE-2; SDR8C1; 17beta-estradiol dehydrogenase type IV; peroxisomal multifunctional protein 2; 17-beta-HSD IV ......
Chromosomal Location	5q2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between HSD17B4 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	HSD17B4
Name	hydroxysteroid (17-beta) dehydrogenase 4
Aliases	MFE-2; SDR8C1; 17beta-estradiol dehydrogenase type IV; peroxisomal multifunctional protein 2; 17-beta-HSD IV ......
Chromosomal Location	5q2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting HSD17B4 collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting HSD17B4.

ID	Name	Drug Type	Targets	#Targets
DB00157	NADH	Small Molecule	AASS, ACADS, ADH1A, ADH1B, ADH1C, ADH4, ADH5, ADH7, AKR1B1, AKR1C1 ......	144
DB03192	3r-Hydroxydecanoyl-Coa	Small Molecule	HSD17B4	1

Browse HSD17B4